Holen Sie sich die Stockscreener-App
0.2634
3.90%
-0.0084
Schlusskurs vom Vortag:
$0.2718
Offen:
$0.2638
24-Stunden-Volumen:
283.09K
Relative Volume:
0.20
Marktkapitalisierung:
$16.82M
Einnahmen:
$1.16M
Nettoeinkommen (Verlust:
$-39.74M
KGV:
-0.4248
EPS:
-0.62
Netto-Cashflow:
$-35.02M
1W Leistung:
-6.91%
1M Leistung:
-0.31%
6M Leistung:
+53.56%
1J Leistung:
-91.32%
1-Tages-Spanne:
$0.259
$0.2696
1-Wochen-Bereich:
$0.2526
$0.2906
52-Wochen-Spanne:
$0.1406
$3.18
Glycomimetics Inc Stock (GLYC) Company Profile
Firmenname
Glycomimetics Inc
Sektor
Branche
Telefon
240-243-1201
Adresse
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Vergleichen Sie GLYC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.259 | 16.82M | 1.16M | -39.74M | -35.02M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.58 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.28 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.40 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.82 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-26 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-22 | Eingeleitet | CapitalOne | Overweight |
| 2021-11-12 | Hochstufung | Jefferies | Hold → Buy |
| 2019-11-14 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-05 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-12-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-07-26 | Eingeleitet | SunTrust | Buy |
| 2015-03-17 | Bestätigt | Stifel | Buy |
Alle ansehen
Glycomimetics Inc Aktie (GLYC) Neueste Nachrichten
GlycoMimetics, Inc. Announces Board Resignations -February 25, 2025 at 05:00 pm EST - Marketscreener.com
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics Says Following Termination, Co Will Not Have Any Material Financial Or Other Obligations Under Agreement - TradingView
GlycoMimetics ends key agreement; board members, executives depart By Investing.com - Investing.com South Africa
GlycoMimetics ends key agreement; board members, executives depart - Investing.com
GlycoMimetics Faces Leadership Changes Amid Board Resignations - TipRanks
US Penny Stocks To Watch In February 2025 - Yahoo Finance
GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update - Defense World
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week - NewsBreak
GlycoMimetics adjusts merger terms with Crescent Biopharma - MSN
GlycoMimetics And GENFIT Announce Significant Agreement Amendments - Evrim Ağacı
GlycoMimetics adjusts merger terms with Crescent Biopharma By Investing.com - Investing.com UK
GLYCOMIMETICS INC SEC 10-K Report - TradingView
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
Glycomimetics, Inc. Announces Cessation of Brian Hahn as Chief Financial Officer, No Later Than March 31, 2025 - Marketscreener.com
Glycomimetics, Inc. Announces Cessation of Harout Semerjian as Chief Executive Officer, No Later Than March 31, 2025 - Marketscreener.com
Reviewing PureTech Health (NASDAQ:PRTC) and GlycoMimetics (NASDAQ:GLYC) - Defense World
StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics executives to depart amid merger plans By Investing.com - Investing.com South Africa
GlycoMimetics executives to depart amid merger plans - MSN
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? - MSN
GlycoMimetics and Crescent Biopharma Update Investor Presentation in Connection with Proposed Merger - Defense World
GlycoMimetics and Crescent Biopharma Announce Merger Plans - Yahoo Finance
Avacta Appoints Brian Hahn as Chief Financial Officer - The Manila Times
Avacta Appoints Brian Hahn as Chief Financial Officer - GlobeNewswire Inc.
GlycoMimetics (NASDAQ:GLYC) Earns Sell Rating from Analysts at StockNews.com - Defense World
Is It Time For Me To Buy GlycoMimetics Inc (NASDAQ: GLYC) Stock Now? - Stocks Register
GlycoMimetics Receives Extension Notice from Nasdaq Regarding Minimum Bid Price ComplianceOn December 19, 2024, GlycoMimetics, Inc. (NASDAQ: GLYC) disclosed in an 8-K filing with the Securities and Exchange Commission that it had received an e - Defense World
GlycoMimetics, Inc. announced that it expects to receive $200 million in funding - Marketscreener.com
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
GlycoMimetics skyrockets on buyout deal - MSN
Logos Global Management LP Acquires 5 Million Shares in GlycoMim - GuruFocus.com
GlycoMimetics: Q3 Earnings Snapshot - Darien Times
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - Quantisnow
Crescent Biopharma to Showcase Cancer Drug Pipeline at Jefferies Healthcare Conference - StockTitan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, PFIE, GLYC on Behalf of Shareholders - The Malaysian Reserve
Finansavisen - Finansavisen
RA Capital Management's Strategic Acquisition of GlycoMimetics I - GuruFocus.com
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - BioSpace
Finanzdaten der Glycomimetics Inc-Aktie (GLYC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Glycomimetics Inc-Aktie (GLYC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10% Owner |
Aug 07 '24 |
Sale |
0.18 |
61,488 |
11,197 |
6,578,438 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 05 '24 |
Sale |
0.19 |
164,523 |
30,996 |
6,695,658 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 06 '24 |
Sale |
0.18 |
55,732 |
10,188 |
6,639,926 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 02 '24 |
Sale |
0.20 |
286,200 |
57,354 |
6,860,181 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 01 '24 |
Sale |
0.22 |
63,564 |
13,743 |
7,146,381 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 30 '24 |
Sale |
0.22 |
756,835 |
167,185 |
7,209,945 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 29 '24 |
Sale |
0.24 |
363,949 |
85,637 |
7,966,780 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 26 '24 |
Sale |
0.24 |
258,335 |
62,440 |
8,330,729 |
| Rock Edwin | Chief Medical Officer |
Jun 20 '24 |
Buy |
0.25 |
190,000 |
48,108 |
565,403 |
| Rock Edwin | Chief Medical Officer |
Jun 21 '24 |
Buy |
0.27 |
115,000 |
30,716 |
680,403 |
3.23%
1.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):